Skip to main content
SpringerLink
Log in

Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects

  • Research Articles
  • Drug Actions
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

The genetically polymorphic CYP2C9 metabolizes many non-steroidal anti-inflammatory agents, including naproxen. This study examined the effects of a CYP2C9 genetic polymorphism on the pharmacokinetics of naproxen in Korean subjects. Twenty healthy male subjects carrying a CYP2C9*1/*1 (n=14) or CYP2C9*1/*3 (n=6) polymorphism were enrolled. After a single-dose of 275 mg naproxen Na, blood samples were collected at various times over a 72 h period and the plasma naproxen concentration was measured. The plasma concentration of naproxen was determined by HPLC analysis with UV detection, and the pharmacokinetic parameters were calculated. The mean plasma concentration-time profiles of naproxen in the CYP2C9*1/*3 and CYP2C9*1/*1 individuals were similar. There were no significant differences in the pharmacokinetics of naproxen between CYP2C9*1/*1 and CYP2C9*1/*3 genotypes. The AUC0-∞ (p = 0.759) and oral clearance (p = 0.823) of naproxen were also similar in individuals with CYP2C9*1/*3 and CYP2C9*1/*1. Overall, a genetic polymorphism of CYP2C9 does not significantly affect the pharmacokinetics of naproxen. Therefore, naproxen does not require a dose adjustment for individuals with the CYP2C9*1/*3 genotype.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Andersen, J. V. and Hansen, S. H., Simultaneous quantitative determination of naproxen, its metabolite 6-O-desmethylnaproxen and their five conjugates in plasma and urine samples by high-performance liquid chromatography on dynamically modified silica. J. Chromatogr., 577, 325–333 (1992).

    Article  PubMed  CAS  Google Scholar 

  • Bae, J. W., Kim, H. K., Kim, J. H., Yang, S. I., Kim, M. J., Jang, C. G., Park, Y. S., and Lee, S. Y., Allele and genotype frequencies of CYP2C9 in a Korean population. Br. J. Clin. Pharmacol., 60, 418–422 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Becker, M. L, Visser, L. E., Trienekens, P. H., Hofman, A., van Schaik, R. H., and Stricker, B. H., Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin. Pharmacol. Ther. 83, 288–292 (2008).

    Article  PubMed  CAS  Google Scholar 

  • Chen, G., Jiang, S., Mao, G., Zhang, S., Hong, X., Tang, G., Li, Z., Liu, X., Zhang, Y., Xing, H., Wang, B., Yu, Y., and Xu, X., CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients. Methods Find Exp. Clin. Pharmacol. 28, 19–24 (2006).

    Article  PubMed  Google Scholar 

  • DeArmond, B., Francisco, C. A., Lin, J. S., Huang, F. Y., Halladay, S., Bartziek, R. D., and Skare, K. L., Safety profile of over-the-counter naproxen sodium. Clin. Ther., 17, 587–601 (1995).

    Article  PubMed  CAS  Google Scholar 

  • Dollery, C., Therapeutic Drugs, 2nd ed. Churchill Livingstone, London, N31–N36 (1999).

    Google Scholar 

  • Foster, R. T., Jamali, F., Russell, A. S., and Alballa, S. R., Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses. J. Pharm. Sci., 77, 70–73 (1988).

    Article  PubMed  CAS  Google Scholar 

  • Hamman, M. A., Haehner-Daniels, B. D., Wrighton, S. A., Rettie, A. E., and Hall, S. D., Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes. Biochem. Pharmacol., 60, 7–17 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available from www.cypalleles.ki.se/cyp2c9.htm. Accessed August 11, 2008.

  • Kiang, C. H., Lee, C., and Kushinsky, S., Isolation and identification of 6-desmethylnaproxen sulfate as a new metabolite of naproxen in human plasma. Drug Metab. Dispos. 17, 43–48 (1989).

    PubMed  CAS  Google Scholar 

  • Kidd, R. S., Straughm, A. B., Meyer, M. C., Blaisdell, J., Goldstein, J. A., and Dalton, J. T., Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 9, 71–80 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Lee, C. R., Pieper, J. A., Frye, R. F., Hinderliter, A. L., Blaisdell, J. A., and Goldstein, J. A., Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Eur. J. Clin. Pharmacol. 58, 791–794 (2003).

    PubMed  CAS  Google Scholar 

  • Lee, Y. J., Kim, Y. G., Lee, M. G., Chung, S. J., Lee, M. H., and Shim, C. K., Analysis of bioequivalence study using log-transformed model. Yakhakhoeji 44, 308–314 (2000).

    Google Scholar 

  • Liu, Y. L., Zhang, W., Tan, Z. R., Ouyang, D. S., Luo, C. H., Liu, Z. Q., Qiu, Y., Chen, Y., He, Y. J., Zhou, G., and Zhou, H. H., Effect of the CYP2C9*3 allele on lornoxicam metabolism. Clin. Chim. Acta. 364, 287–291 (2006).

    Article  PubMed  CAS  Google Scholar 

  • Liu, Y. L., Zhang, W., Tan, Z. R., Ouyang, D. S., Luo, C. H., Liu, Z. Q., Qiu, Y., Chen, Y., He, Y. J., Zhou, G., and Zhou, H. H., Effect of the CYP2C9*3 allele on lornoxicam metabolism. Clin. Chim. Acta 364, 287–291 (2006).

    Article  PubMed  CAS  Google Scholar 

  • Miner, J. O. and Birkett, D. J., Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol., 45, 525–538 (1998).

    Article  Google Scholar 

  • Miners, J. O., Coulter, S., Tukey, R. H., Veronese, M. E., and Birkett, D. J., Cytochrome P450, 1A2, and 2C9 are responsible for the human hepatic o-desmethylation of Rand S-naproxen, Biochem. Pharmacol. 51, 1003–1008 (1996).

    Article  PubMed  CAS  Google Scholar 

  • Myrand, S., Sekiguchi, K., Man, M., Lin, X., Tzeng, R. Y., Teng, C. H., Hee, B., Garrett, M., Kikkawa, H., Lin, C. Y., Eddy, S. M., Dostalik, J., Mount, J., Azuma, J., Fujio, Y., Jang, I. J., Shin, S. G., Bleavins, M. R., Williams, J. A., Paulauskis, J. D., and Wilner, K. D., Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First- and Third-generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian Populations. Clin. Pharmacol. Ther., 84, 347–361 (2008).

    Article  PubMed  CAS  Google Scholar 

  • Perini, J. A., Vianna-Jorge, R., Brogliato, A. R., and Suarez-Kurtz, G., Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin. Pharmacol. Ther., 78, 362–369 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Rendic, S. and di Carlo, F. J., Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev., 29, 413–580 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Rodrigues, A. D., Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab. Dispos., 33, 1567–1575 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Rodrigues, A. D., Kukulka, M. J., Roberts, E. M., Ouellet, D., and Rodgers, T. R., [O-Methyl 14C] naproxen o-desmethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10, Drug Metab. Dispos., 24, 126–136 (1996).

    PubMed  CAS  Google Scholar 

  • Sandberg, M., Yasar, U., Strömberg, P., Höög, J. O., and Eliasson, E., Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br. J. Clin. Pharmacol., 54, 423–429 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Suzuki, K., Yanagawa, T., Shibasaki, T., Kaniwa, N., Hasegawa, R., and Tohkin, M., Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res. Clin. Pract., 72, 148–154 (2006).

    Article  PubMed  CAS  Google Scholar 

  • Thomson, G. F. and Collins, G. M., Urinary metabolic profiles for choosing test animals for chronic toxicity studies: application to naproxen. J. Pharm. Sci., 62, 937–941 (1973)

    Article  Google Scholar 

  • Tracy, T. S., Marra, S., Wrighton, S. A., Gonzalez, F. J., and Korzekwa, K.R., Involvement of multiple cytochrome P450 isoforms in naproxen O-desmethylation, Eur. J. Clin. Pharmacol., 52, 293–298 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Vianna-Jorge, R., Perini, J. A., Rondinelli, E., and Suarez-Kurtz, G., CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin. Pharmacol. Ther., 76, 18–26 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Xie, H. G., Prasad, H. C., Kim, R. B., and Stein, C. M., CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliver. Rev., 54, 1257–1270 (2002).

    Article  CAS  Google Scholar 

  • Yoon, Y. R., Shon, J. H., Kim, M. K., Lim, Y. C., Lee, H. R., Park, J. Y., Cha, I. J., and Shin J. G., Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol., 51, 277–280 (2001).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, Sungkyunkwan University, Suwon, 440-746, Korea

    Jung-Woo Bae, Ji-Hong Kim, Chang-Ik Choi, Mi-Jeong Kim, Hyung-Ji Kim, Seong-Ae Byun, Young-Soon Chang, Choon-Gon Jang & Seok-Yong Lee

  2. Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical Centre, Seoul, Korea

    Young-Seo Park

  3. Lab. of Pharmacology, College of Pharmacy, Sungkyunkwan University, Suwon, 440-746, Republic of Korea

    Seok-Yong Lee

Authors
  1. Jung-Woo Bae
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ji-Hong Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chang-Ik Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mi-Jeong Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hyung-Ji Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seong-Ae Byun
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Young-Soon Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Choon-Gon Jang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Young-Seo Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Seok-Yong Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seok-Yong Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bae, JW., Kim, JH., Choi, CI. et al. Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects. Arch. Pharm. Res. 32, 269–273 (2009). https://doi.org/10.1007/s12272-009-1232-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-009-1232-z

Key words

Search

Navigation